Our long-term vision is to pioneer a transformative era in ​regenerative medicine, akin to the groundbreaking impact ​seen in the biopharma industry's history. We aim to be at the ​forefront of this revolution, developing cutting-edge ​regenerative therapies, the hydrogel and ML-aided motor ​neuron and intestinal stem cell therapies, that set new ​standards for ALS and IBD patient care respectively. Our goal ​is to establish an internal ecosystem of innovation and ​excellence in regenerative medicine, empowering not only our ​endeavors but also inspiring and enabling the broader ​industry to achieve transformative patient outcomes through ​regenerative therapies.

Materials

Biology

Computation

• Principal Scientist @ Genentech; ​Research focus on biomaterials & tissue ​engineering
• PhD in Chemical Engineering @ CU ​Boulder
• MBA @ Stanford GSB
  

• Publications in Nature & Science (1st ​author paper in Nature)
• PhD in Biology in Aging @ USC & Buck ​Institute
  

• Research focus on AI/ML in ​bioengineering, traumatic brain injury
• PhD in Bioengineering and Biomedical ​Data Science@ Stanford
  

Terminal Disease Cure

Developing personalized treatments for ​a range of terminal diseases

Regenerative Therapy

Utilizing machine learning and ​biosynthetic materials to rejuvenate ​tissue function